NIR 178

Drug Profile

NIR 178

Alternative Names: NIR178; PBF-509

Latest Information Update: 18 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palobiofarma
  • Developer Novartis; Palobiofarma
  • Class Antineoplastics; Antiparkinsonians; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Cancer; Lung cancer
  • No development reported Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 12 Jun 2018 Phase-I clinical trials in Cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03549000)
  • 01 Jun 2018 Interim adverse events, pharmacokinetics and efficacy data from the phase I/II AdenONCO trial for Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 29 Oct 2015 PBF 509 licensed to Novartis worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top